Tazeen Ahmad
Stock Analyst at B of A Securities
(3.26)
# 1,019
Out of 4,944 analysts
202
Total ratings
45.33%
Success rate
2.04%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $126 → $134 | $111.00 | +20.72% | 9 | Aug 5, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $68 → $84 | $45.27 | +85.55% | 18 | Jul 29, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Underperform | $20 → $10 | $18.80 | -46.81% | 24 | Jul 23, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $23 → $24 | $23.90 | +0.42% | 8 | Jul 16, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $336 → $359 | $429.93 | -16.50% | 4 | Jul 11, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Buy | $8 | $2.91 | +174.91% | 1 | Jul 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $73 → $95 | $96.39 | -1.44% | 9 | Jul 10, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Buy | $13 → $15 | $8.35 | +79.64% | 12 | Jul 1, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $201 → $216 | $196.02 | +10.20% | 10 | Jun 9, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $18 → $23 | $25.45 | -9.63% | 15 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $7.54 | -46.95% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $1 → $0.8 | $0.78 | +2.08% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $13.22 | +104.24% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $6.80 | +312.07% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $63.76 | +9.79% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $6.15 | +550.41% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $128.89 | +38.88% | 3 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $12.25 | +79.59% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.14 | +163.16% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $81.61 | +10.28% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.98 | +114.90% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $6.54 | -69.42% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $637.40 | -4.77% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $28.11 | +170.37% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.43 | +311.52% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $0.94 | +540.82% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.48 | +20.24% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $21.09 | -47.84% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $2.94 | -31.97% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.84 | +615.99% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $10.61 | +41.38% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $48.46 | +23.81% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.04 | +1,438.46% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $9.04 | +375.66% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $204.55 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $9.81 | +2,958.10% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.36 | +281.36% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $24.81 | +93.47% | 6 | Oct 10, 2018 |
BioNTech SE
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $111.00
Upside: +20.72%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $68 → $84
Current: $45.27
Upside: +85.55%
Sarepta Therapeutics
Jul 23, 2025
Downgrades: Underperform
Price Target: $20 → $10
Current: $18.80
Upside: -46.81%
Apellis Pharmaceuticals
Jul 16, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $23.90
Upside: +0.42%
Alnylam Pharmaceuticals
Jul 11, 2025
Maintains: Buy
Price Target: $336 → $359
Current: $429.93
Upside: -16.50%
Taysha Gene Therapies
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $2.91
Upside: +174.91%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $96.39
Upside: -1.44%
BioCryst Pharmaceuticals
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $8.35
Upside: +79.64%
Ascendis Pharma
Jun 9, 2025
Maintains: Buy
Price Target: $201 → $216
Current: $196.02
Upside: +10.20%
ACADIA Pharmaceuticals
Jun 5, 2025
Maintains: Neutral
Price Target: $18 → $23
Current: $25.45
Upside: -9.63%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $7.54
Upside: -46.95%
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.78
Upside: +2.08%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $13.22
Upside: +104.24%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $6.80
Upside: +312.07%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $63.76
Upside: +9.79%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $6.15
Upside: +550.41%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $128.89
Upside: +38.88%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $12.25
Upside: +79.59%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.14
Upside: +163.16%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $81.61
Upside: +10.28%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.98
Upside: +114.90%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $6.54
Upside: -69.42%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $637.40
Upside: -4.77%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $28.11
Upside: +170.37%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.43
Upside: +311.52%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $0.94
Upside: +540.82%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $12.48
Upside: +20.24%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $21.09
Upside: -47.84%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $2.94
Upside: -31.97%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.84
Upside: +615.99%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $10.61
Upside: +41.38%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $48.46
Upside: +23.81%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.04
Upside: +1,438.46%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $9.04
Upside: +375.66%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $204.55
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $9.81
Upside: +2,958.10%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.36
Upside: +281.36%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $24.81
Upside: +93.47%